Ann Arbor, Mich.– OcuSciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted marketing clearance for its flagship device, the OcuMet Beacon, a non-invasive retinal imaging tool designed to assist clinicians in assessing retinal health. The announcement was made in conjunction with the ARVO 2025 conference, where the company is showcasing the device.
The OcuMet Beacon is a confocal scanning ophthalmoscope indicated for infrared (IR) and autofluorescence (AF) imaging of the human retina, with or without the use of a mydriatic agent. The system captures a naturally occurring fluorescence from the retina using proprietary illumination and detection technology, and translates it into visual data through advanced imaging software.
“With our collaborators, we are extending the depth of understanding for retinal diseases,” said Kurt Riegger, CEO of OcuSciences. “This is a game-changer for patients and ophthalmologists alike. The OcuMet Beacon provides clinicians with valuable information in just seconds.”
Designed for speed, comfort, and clinical efficiency, the OcuMet Beacon eliminates the need for injections, dyes, or physical contact with the eye. Imaging takes only a few minutes and can be easily integrated into routine eye exams and paired with standard treatment protocols.
FDA clearance allows OcuSciences to make the OcuMet Beacon available to clinics and healthcare institutions across the United States. The device has been validated in numerous peer-reviewed studies, with a growing body of research demonstrating its safety, efficacy, and potential to improve patient outcomes. At ARVO 2025, more than a dozen new studies will be presented to further support its clinical utility.
OcuSciences is now working with key opinion leaders and eye care providers to accelerate nationwide adoption of the technology.
